Get the Stockscreener App
0.9131
7.01%
0.0598
Pds Biotechnology Corporation stock is traded at $0.9131, with a volume of 387.11K.
It is up +7.01% in the last 24 hours and up +4.95% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$0.8533
Open:
$0.841
24h Volume:
387.11K
Relative Volume:
0.51
Market Cap:
$49.98M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-0.7804
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
+13.70%
1M Performance:
+4.95%
6M Performance:
-31.35%
1Y Performance:
-46.60%
1-Day Range:
$0.8335
$0.92
1-Week Range:
$0.762
$0.92
52-Week Range:
$0.703
$2.20
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.9133 | 46.69M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
Aug Sentiment: How PDS Biotechnology Corporation stock trades during market volatility2025 Pullback Review & Entry and Exit Point Strategies - Улправда
How interest rate cuts could boost PDS Biotechnology Corporation stockSell Signal & Reliable Entry Point Alerts - Улправда
Guidance Update: Does PDS Biotechnology Corporation stock trade at a discount to peersMarket Volume Report & Verified Momentum Watchlists - Улправда
Can PDS Biotechnology Corporation stock sustain institutional interest2025 Pullback Review & Weekly Chart Analysis and Trade Guides - DonanımHaber
Does PDS Biotechnology Corporation stock trade at a discount to peersJuly 2025 Summary & Long-Term Capital Growth Ideas - ulpravda.ru
Will PDS Biotechnology Corporation stock continue upward momentum2025 Institutional Moves & Daily Market Momentum Tracking - bolumsonucanavari.com
How PDS Biotechnology Corporation stock performs after earningsJuly 2025 Update & Capital Efficiency Focused Ideas - DonanımHaber
Is PDS Biotechnology Corporation stock resilient to inflation2025 Big Picture & Weekly Market Pulse Updates - DonanımHaber
Aug Spikes: How supply chain issues affect PDS Biotechnology Corporation stockWeekly Market Outlook & Real-Time Volume Trigger Notifications - moha.gov.vn
PDS Biotechnology (NASDAQ:PDSB) Shares Down 1.9% – Here’s What Happened - Defense World
Stocks of PDS Biotechnology Corporation (PDSB) are poised to climb above their peers - setenews.com
PDS Biotech secures new patent for cancer immunotherapy in Japan By Investing.com - Investing.com Australia
PDS Biotechnology Secures New Patent for PDS0101 - TipRanks
PDS Biotech secures new patent for cancer immunotherapy in Japan - Investing.com
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan - The Manila Times
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why - sharewise.com
EPS Watch: How interest rate cuts could boost PDS Biotechnology Corporation stockTrade Risk Report & Precise Buy Zone Tips - moha.gov.vn
How supply chain issues affect PDS Biotechnology Corporation stock2025 Macro Impact & AI Powered Market Trend Analysis - Newser
A better buy-in window may exist right now for PDS Biotechnology Corporation (PDSB) - setenews.com
Is PDS Biotechnology Corporation stock ready for breakoutOptions Play & Real-Time Volume Spike Alerts - Newser
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration - marketscreener.com
PDS Biotech secures FDA meeting to discuss accelerated approval pathway By Investing.com - Investing.com Nigeria
PDS Biotech secures FDA meeting to discuss accelerated approval pathway - Investing.com
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ('FDA”) - The Manila Times
PDS Biotech announces scheduling of Type C meeting with U.S. Food and Drug Administration - marketscreener.com
PDS Biotech (Nasdaq: PDSB) Plans FDA Talk on PFS Endpoint in VERSATILE-003 Trial - Stock Titan
Energy Moves: How interest rate cuts could boost PDS Biotechnology Corporation stock2025 Volatility Report & Capital Efficiency Focused Ideas - moha.gov.vn
Adversity is less terrifying than hope: PDS Biotechnology Corporation (PDSB) - Setenews
B. Riley Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $3.00 - Defense World
History Review: How interest rate cuts could boost PDS Biotechnology Corporation stockPortfolio Growth Summary & Precise Buy Zone Tips - moha.gov.vn
PDS Biotechnology price target lowered to $3 from $5 at B. Riley - Yahoo Finance
B. Riley Securities Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
B. Riley Adjusts Price Target on PDS Biotechnology to $3 From $5, Maintains Buy Rating - marketscreener.com
Can PDS Biotechnology Corporation stock reach $100 price targetMarket Performance Report & Growth Focused Investment Plans - newser.com
PDS Biotechnology Shares Face Market Pressure Despite Clinical Promise - Ad-hoc-news.de
What dividend safety score for PDS Biotechnology Corporation stock2025 Market Overview & Real-Time Volume Analysis Alerts - newser.com
Why PDS Biotechnology Corporation stock is recommended by analysts2025 Top Decliners & Growth Focused Stock Reports - newser.com
Earnings visualization tools for PDS Biotechnology CorporationOil Prices & Verified Technical Signals - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedInflation Watch & Breakout Confirmation Alerts - newser.com
Advanced analytics toolkit walkthrough for PDS Biotechnology CorporationCPI Data & Daily Oversold Bounce Ideas - newser.com
Is PDS Biotechnology Corporation stock a good choice for value investorsInflation Watch & Safe Entry Point Identification - newser.com
It makes sense and dollars to buy PDS Biotechnology Corporation (PDSB) stock - Setenews
Is PDS Biotechnology Corporation stock entering bullish territoryJuly 2025 Highlights & Consistent Growth Equity Picks - newser.com
PDS Biotechnology Corp (EU6.DU) stock price, news, quote and history - Yahoo Finance Singapore
Tools to assess PDS Biotechnology Corporation’s risk profilePortfolio Performance Report & Consistent Return Investment Signals - newser.com
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pds Biotechnology Corporation Stock (PDSB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Glover Stephen C. | Director |
Feb 28 '25 |
Buy |
1.66 |
15,061 |
25,001 |
78,851 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):